Vibha Sharma
Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She joined Scrip Regulatory Affairs in September 2010 and has since then been at the center of deciding and writing news on important regulatory issues affecting the pharma and medtech sectors and explaining their implications for the industry.
Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.
Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Vibha Sharma
EU Takes Dispute With Turkey On Localization Policy To Next Level
After unsuccessful negotiations with Turkey on its discriminatory policies against foreign drug producers, the EU has asked the World Trade Organization to set up a dispute settlement panel to resolve the matter.
EU Warns Of Birth Defect Risks With Anti-Nausea Drug Ondansetron
Sponsors of medicines containing ondansetron in the EU have been given two months to update their product information to state that the drug should not be used in early pregnancy.
End Of Road For ‘Too Complex’ EU Pilot Program On Splitting Marketing Licenses
EU regulators have pulled the plug on a pilot program on splitting mutual recognition and decentralized procedure licences. Instead of promoting harmonization of marketing authorizations across the EU and helping companies with their marketing strategies, it has led to more problems.
End Of Road For ‘Too Complex’ EU Pilot On Splitting Marketing Licenses
EU regulators have pulled the plug on a pilot program on splitting mutual recognition and decentralized procedure licences. Instead of promoting harmonization of marketing authorizations across the EU and helping companies with their marketing strategies, it has led to more problems.
Canada Consults On Customized Rules For Approving Unique Devices, Drugs
Health Canada is inviting suggestions from stakeholders as it works on implementing a flexible approach for authorizing complex and novel health products. The regulator also draws up new clinical trial rules.
Canada Consults On Customized Rules For Approving Unique Drugs, Devices
Health Canada is inviting suggestions from stakeholders as it works on implementing a flexible approach for authorizing complex and novel health products. The regulator also draws up new clinical trial rules.
Advertisement